U.S. Hedge Funds are buying cannabis stocks. Despite regulatory issues and limited investment choices, the "smart money" is increasingly eager to gain exposure to the booming marijuana sector. But you won't see Warren Buffett and Charlie Munger jumping on the pot stock...
Below is a list of the top ten most overrated hedge fund managers. Many of these guys (they're all men) have become celebrities, idolized by investors, just like movie stars or great athletes are in mainstream American society. And most of them made their billions -- and...
On March 4, Marathon Partners called ELF Beauty "undervalued" in a 13D filing with the SEC. The New York City-based hedge fund disclosed a 5.2% stake, and said in the filing it has "engaged, and plans to continue to engage, with the Issuer’s management and Board of...
On December 27, 2018, Cannell Capital LLC — a hedge fund based in Alta, Wyoming – disclosed sending three separate letters to three company managements, notifying them of Cannell’s activist intentions. Buying the stocks targeted by Cannell on that date would have produced an average gain of 32.40% over the 25 trading days since.
Light Street Capital filed a 13G on Monday July 22, disclosing a 5.2% stake in cybersecurity firm Carbon Black, Inc. (CBLK). The Palo Alto-based hedge fund acquired the $69 million CBLK position as cyber attacks become an increasing problem for U.S. corporations, and...
The best performing hedge funds are often ones you haven't heard of. You're not doubt familiar with Berkshire Hathaway and Bridgewater Associates. But you probably don't know Casdin Capital or King Street Management. While investors fawned over Bridgewater's 14.6% gain...
GE is another Enron, only worse. That's according to forensic accountant Harry Markopolos, famous for raising red flags about Bernie Madoff ’s Ponzi scheme before most anyone else had a clue. Markipolos released a report on Thursday claiming General Electric (GE) has been...
Hudson Executive Capital disclosed on Monday that it bought 143,200 shares of USA Technology (USAT) at $4.46 along with call options giving the fund the right to buy another 1,250,000 shares of stock at $10. The call options expire on Jan. 17, 2020.
Perceptive Advisors' Neptune Wellness Solutions (NEPT) position increased by 50% during the 3rd quarter of 2019, to 4.5 million shares. The stake represents 14.53% of the Cannabis extraction company's outstanding shares. NEPT was Perceptive Advisors' #20 position at Q3 close. The increase in Perceptive'...
Engine Capital filed a 13D on Cymabay (CBAY) two weeks after the development stage biotech company halted a trial of its leading drug candidate causing it's shares to fall as much as 75%. In a 13D filing Thursday evening, New York-based Engine Capital, L.P....